Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
May 09, 2021 at 07:46 pm
Share
Chi Sheng Pharma & Biotech Co. Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was TWD 239.479 million compared to TWD 265.684 million a year ago. Operating income was TWD 11.014 million compared to TWD 30.932 million a year ago. Net income was TWD 12.722 million compared to TWD 25.949 million a year ago. Basic earnings per share was TWD 0.22 compared to TWD 0.46 a year ago. Diluted earnings per share was TWD 0.22 compared to TWD 0.45 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
CHI SHENG PHARMA & BIOTECH CO., LTD 
